ELVN

Enliven Therapeutics, Inc. ELVN

ELVN
Enliven Therapeutics, Inc. OLMA
Olema Pharmaceuticals, Inc. IRON
Disc Medicine, Inc. LRMR
Larimar Therapeutics, Inc. FENC
Fennec Pharmaceuticals Inc. OBIO
Orchestra BioMed Holdings, Inc. BMEA
Biomea Fusion, Inc. TYRA
Tyra Biosciences, Inc. NUVL
Nuvalent, Inc. VTYX
Ventyx Biosciences, Inc.

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode ELVN OLMA IRON LRMR FENC OBIO BMEA TYRA NUVL VTYX
6M 26.11 % 180.37 % 80.48 % 140.88 % 71.06 % 5.70 % -4.00 % 69.85 % 32.90 % 267.58 %
YTD -12.89 % 89.77 % 11.93 % 8.73 % 36.25 % -41.45 % -54.47 % -6.31 % 10.14 % 66.36 %
1Y -24.97 % -9.89 % 45.66 % -39.86 % 88.77 % -39.07 % -83.86 % -38.60 % -14.71 % 52.14 %
3Y 101.74 % 257.09 % 321.08 % 38.41 % 6.46 % -68.28 % -82.05 % 112.24 % 307.87 % -88.27 %
5Y -73.77 % -78.43 % -36.45 % -76.94 % 15.81 % -71.23 % -90.12 % -48.00 % 369.87 % -83.06 %
10Y -65.30 % -78.43 % -32.14 % -97.69 % -28.58 % -72.37 % -90.12 % -48.00 % 369.87 % -83.06 %
From the beginning -65.30 % -78.43 % -32.14 % -98.16 % -28.58 % -72.37 % -90.12 % -48.00 % 369.87 % -83.06 %

Dividend